drugset / Trial / NCT01369472
Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule
RandomizedCrossoverOpen-labelTreatment
Summary
This study is designed to evaluate dose-proportionality of Dilatrend SR 8mg, 16mg, 32mg, 64mg, 128mg in healthy male volunteers.
Timeline
- Start
- 2011-06
- Primary completion
- 2011-10
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dilatrend SR capsule | Unknown | 8 mg | Oral |
| Subject | Dilatrend SR capsule | Unknown | 16 mg | Oral |
| Subject | Dilatrend SR capsule | Unknown | 32 mg | Oral |
| Subject | Dilatrend SR capsule | Unknown | 64 mg | Oral |
| Subject | Dilatrend SR capsule | Unknown | 128 mg | Oral |